We retrieved the clinical data of LUAD patients treated with CTLA-4 or/and PD-1 from The Cancer Immunome Atlas (TCIA) database and observed that high-risk patients may benefit more from immunotherapy (Figure 8A–8D). This evidence concerns the gene CTLA4 and cancer.